Terconazole - Padagis Israel Pharmaceuticals Ltd

Manufacturer
Padagis Israel Pharmaceuticals Ltd
Effective date
2026-08-11
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
15
Source
daily-update
Hydrated at
2026-08-13 01:01:48

Label at a glance#

ProductTerconazole
Active ingredientTERCONAZOLE
Label structure15 sections

Indications and uses

Terconazole Vaginal Suppositories, 80 mg are indicated for the local treatment of vulvovaginal candidiasis (moniliasis). As this product is effective only for vulvovaginitis caused by the genus Candida, the diagnosis should be confirmed by KOH smears and/or cultures.

Dosage and administration

One Terconazole Vaginal Suppository, 80 mg should be administered intravaginally once daily at bedtime for three consecutive days. Before prescribing another course of therapy, the diagnosis should be reconfirmed by smears and/or cultures and other pathogens commonly associated with vulvovaginitis ruled out. The therapeutic effect of terconazole vaginal suppositories is not affected by menstruation.

Storage and handling

Store at 20-25°C (68-77°F) [see USP Controlled Room Temperature].

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx Only

DESCRIPTION

DESCRIPTION SECTION

Terconazole Vaginal Suppositories, 80 mg are white to off-white suppositories for intravaginal administration containing 80 mg of the antifungal agent terconazole, cis-1-[p-[[2-(2,4-Dichlorophenyl)-2- (1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-isopropylpiperazine, in triglycerides derived from coconut and/or palm kernel oil (a base of hydrogenated vegetable oils) and butylated hydroxyanisole.

The structural formula of terconazole is as follows:

Structural Formula.jpg
Structural Formula.jpg

Terconazole, a triazole derivative, is a white to almost white powder with a molecular weight of 532.47. It is insoluble in water; sparingly soluble in ethanol; and soluble in butanol.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Absorption - Following a single intravaginal application of a suppository containing 240 mg 14C-terconazole to healthy women, approximately 70% (range: 64-76%) of terconazole remains in the vaginal area during the suppository retention period (16 hours); approximately 10% (range: 5-16%) of the administered radioactivity was absorbed systemically over 7 days. Maximum plasma concentrations of terconazole occur 5 to 10 hours after intravaginal application of the suppository. Systemic exposure to terconazole is approximately proportional to the applied dose. The rate and extent of absorption of terconazole are similar in patients with vulvovaginal candidiasis (pregnant or non-pregnant) and healthy subjects.

Distribution - Terconazole is highly protein bound (94.9%) in human plasma and the degree of binding is independent of drug concentration over the range of 0.01 to 5.0 mcg/mL.

Metabolism - Systemically absorbed terconazole is extensively metabolized (>95%).

Elimination - Across various studies in healthy women, after single or multiple intravaginal administration of terconazole, the mean elimination half-life of unchanged terconazole ranged from 6.4 to 8.5 hours. Following a single intravaginal administration of a suppository containing 240 mg 14C-terconazole to hysterectomized or tubal ligated women, approximately 3 to 10% (mean ± SD: 5.7 ± 3.0%) of the administered radioactivity was eliminated in the urine and 2 to 6% (mean ± SD: 4.2 ± 1.6%) was eliminated in the feces during the 7-day collection period.

Multiple Dosing - There is no significant increase in maximum plasma concentration or overall exposure (AUC) after multiple daily applications of the suppositories for 3 days.

Photosensitivity reactions have not been observed in U.S. and foreign clinical trials in patients who were treated with terconazole suppositories.

Microbiology

SPL UNCLASSIFIED SECTION

Mechanism of action - Terconazole, an azole antifungal agent, inhibits fungal cytochrome P-450-mediated 14 alpha-lanosterol demethylase enzyme. This enzyme functions to convert lanosterol to ergosterol. The accumulation of 14 alpha-methyl sterols correlates with the subsequent loss of ergosterol in the fungal cell wall and may be responsible for the antifungal activity of terconazole. Mammalian cell demethylation is less sensitive to terconazole inhibition.

Activity in vitro - Terconazole exhibits antifungal activity in vitro against Candida albicans and other Candida species. The MIC values of terconazole against most Lactobacillus spp. typically found in the human vagina were ≥128 mcg/mL; therefore these beneficial bacteria are not affected by drug treatment.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Terconazole Vaginal Suppositories, 80 mg are indicated for the local treatment of vulvovaginal candidiasis (moniliasis). As this product is effective only for vulvovaginitis caused by the genus Candida, the diagnosis should be confirmed by KOH smears and/or cultures.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Patients known to be hypersensitive to terconazole or to any of the components of the suppositories.

WARNINGS

WARNINGS SECTION

Anaphylaxis and toxic epidermal necrolysis have been reported during terconazole therapy. Terconazole Vaginal Suppositories, 80 mg therapy should be discontinued if anaphylaxis or toxic epidermal necrolysis develops.

PRECAUTIONS

PRECAUTIONS SECTION

General -

GENERAL PRECAUTIONS SECTION

For vulvovaginal use only. Terconazole Vaginal Suppositories, 80 mg is not for ophthalmic or oral use. Discontinue use and do not retreat with terconazole if sensitization, irritation, fever, chills or flu-like symptoms are reported during use.

The base contained in the suppository formulation may interact with certain rubber or latex products, such as those used in vaginal contraceptive diaphragms or latex condoms; therefore concurrent use is not recommended.

Laboratory Tests -

LABORATORY TESTS SECTION

If there is a lack of response to terconazole, appropriate microbiologic studies (standard KOH smear and/or cultures) should be repeated to confirm the diagnosis and rule out other pathogens.

Drug Interactions -

DRUG INTERACTIONS SECTION

The therapeutic effect of terconazole is not affected by oral contraceptive usage.

The levels of estradiol and progesterone did not differ significantly when 0.8% terconazole vaginal cream was administered to healthy female volunteers established on a low dose oral contraceptive.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Carcinogenesis -

SPL UNCLASSIFIED SECTION

Studies to determine the carcinogenic potential of terconazole have not been performed.

Mutagenicity -

SPL UNCLASSIFIED SECTION

Terconazole was not mutagenic when tested in vitro for induction of microbial point mutations (Ames test), or for inducing cellular transformation, or in vivo for chromosome breaks (micronucleus test) or dominant lethal mutations in mouse germ cells.

Impairment of Fertility -

SPL UNCLASSIFIED SECTION

No impairment of fertility occurred when female rats were administered terconazole orally up to 40 mg/kg/day for a three month period.

Pregnancy: Teratogenic Effects: Pregnancy Category C -

PREGNANCY SECTION

There was no evidence of teratogenicity when terconazole was administered orally up to 40 mg/kg/day (25x the recommended intravaginal human dose of the suppository formulation) in rats, or 20 mg/kg/day in rabbits, or subcutaneously up to 20 mg/kg/day in rats.

Dosages at or below 10 mg/kg/day produced no embryotoxicity; however, there was a delay in fetal ossification at 10 mg/kg/day in rats. There was some evidence of embryotoxicity in rabbits and rats at 20-40 mg/kg. In rats, this was reflected as a decrease in litter size and number of viable young and reduced fetal weight. There was also delay in ossification and an increased incidence of skeletal variants.

The no-effect dose of 10 mg/kg/day resulted in a mean peak plasma level of terconazole in pregnant rats of 0.176 mcg/mL which exceeds by 17 times the mean peak plasma level (0.010 mcg/mL) seen in normal subjects after intravaginal administration of terconazole 80 mg vaginal suppository. This safety assessment does not account for possible exposure of the fetus through direct transfer to terconazole from the irritated vagina by diffusion across amniotic membranes. Since terconazole is absorbed from the human vagina, it should not be used in the first trimester of pregnancy unless the physician considers it essential to the welfare of the patient.

Terconazole may be used during the second and third trimester if the potential benefit outweighs the possible risks to the fetus.

Nursing Mothers -

NURSING MOTHERS SECTION

It is not known whether this drug is excreted in human milk. Animal studies have shown that rat offspring exposed via the milk of treated (40 mg/kg/orally) dams showed decreased survival during the first few post-partum days, but overall pup weight and weight gain were comparable to or greater than controls throughout lactation. Because many drugs are excreted in human milk, and because of the potential for adverse reaction in nursing infants from terconazole, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use -

PEDIATRIC USE SECTION

Safety and efficacy in children have not been established.

Geriatric Use -

GERIATRIC USE SECTION

Clinical studies of terconazole vaginal suppositories did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Adverse Reactions from Clinical Trials

SPL UNCLASSIFIED SECTION

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

During controlled clinical studies conducted in the United States, 284 patients with vulvovaginal candidiasis were treated with terconazole 80 mg vaginal suppositories. Based on comparative analyses with placebo (295 patients), the adverse experiences considered adverse reactions most likely related to terconazole 80 mg vaginal suppositories were headache (30.3% vs. 20.7% with placebo) and pain of the female genitalia (4.2% vs. 0.7% with placebo). Adverse reactions that have also been reported but were not statistically significantly different from placebo were burning (15.2% vs. 11.2% with placebo) and body pain (3.9% vs. 1.7% with placebo). Fever (2.8% vs. 1.4% with placebo) and chills (1.8% vs. 0.7% with placebo) have also been reported. The adverse drug experience on terconazole most frequently causing discontinuation was burning (2.5% vs. 1.4% with placebo) and pruritus (1.8% vs. 1.4% with placebo).

Post-marketing Experience

SPL UNCLASSIFIED SECTION

The following adverse drug reactions have been first identified during post-marketing experience with Terconazole Vaginal Suppositories, 80 mg. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

General: Asthenia, Influenza-Like Illness consisting of multiple listed reactions including fever and chills, nausea, vomiting, myalgia, arthralgia, malaise

Immune: Hypersensitivity, Anaphylaxis, Face Edema

Nervous: Dizziness

Respiratory: Bronchospasm

Skin: Rash, Toxic Epidermal Necrolysis, Urticaria

OVERDOSAGE

OVERDOSAGE SECTION

In the rat, the oral LD 50 values were found to be 1741 and 849 mg/kg for the male and female, respectively. The oral LD 50 values for the male and female dog were ≅1280 and ≥640 mg/kg, respectively.

In the event of oral ingestion of suppository, supportive and symptomatic measures should be carried out.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

One Terconazole Vaginal Suppository, 80 mg should be administered intravaginally once daily at bedtime for three consecutive days.

Before prescribing another course of therapy, the diagnosis should be reconfirmed by smears and/or cultures and other pathogens commonly associated with vulvovaginitis ruled out. The therapeutic effect of terconazole vaginal suppositories is not affected by menstruation.

HOW SUPPLIED

HOW SUPPLIED SECTION

Terconazole Vaginal Suppositories, 80 mg are available as follows:

Carton containing 3 suppositories (NDC 45802-717-08)

STORAGE

STORAGE AND HANDLING SECTION

Store at 20-25°C (68-77°F) [see USP Controlled Room Temperature].

SPL UNCLASSIFIED SECTION

Manufactured by Padagis®
Minneapolis, MN 55427

www.padagis.com

2204901
Rev 05-24

3B500 RC PH1

Patient Instructions

SPL PATIENT PACKAGE INSERT SECTION

Terconazole Vaginal Suppositories, 80 mg

Three oval suppositories, for use inside the vagina only.

Designed to be inserted into the vagina.

HOW TO USE:

Place one suppository into the vagina each night at bedtime, for 3 nights, as directed by your doctor.

The terconazole vaginal suppository is self-lubricating and may be inserted with or without the applicator.

Image 1
Image 1

A. Insertion with the applicator

1. Filling the applicator

  • Break off suppository from the foil strip.
  • Pull the foil completely apart.
  • Place the flat end of the suppository into the open end of the applicator as shown.
  • You are now ready to insert the suppository into the vagina.
Image 2
Image 2

2. Using the applicator

  • Lie on your back with your knees drawn up toward your chest.
  • Holding the applicator by the ribbed end of the barrel, gently insert it into the vagina as far as it will comfortably go.
  • Press the plunger to release the suppository into the vagina.
  • Remove the applicator from the vagina.
Image 3
Image 3

3. Cleaning the applicator

After each use, you should thoroughly clean the applicator by following the procedure below:

  • Pull the plunger out of the barrel.
  • Wash both pieces with lukewarm, soapy water, and dry them thoroughly.
  • Put the applicator back together by gently pushing the plunger into the barrel as far as it will go.

B. Insertion without the applicator

  • Lie on your back with your knees drawn up toward your chest.
  • Place the suppository on the tip of your finger as shown.
  • Insert the suppository gently into the vagina as far as it will comfortably go.
Image 4
Image 4

STORAGE:

Store at 20-25°C (68-77°F) [see USP Controlled Room Temperature].

See end flap for lot number and expiration date.

A WORD ABOUT YEAST INFECTIONS

Why do yeast infections occur?

Yeast infections are caused by an organism called Candida (KAN di duh). It may be present in small and harmless amounts in the mouth, digestive tract, and vagina. Sometimes the natural balance of the vagina becomes upset. This may lead to rapid growth of Candida, which results in a yeast infection. Symptoms of a yeast infection include itching, burning, redness, and an abnormal discharge.

Your doctor can make the diagnosis of a yeast infection by evaluating your symptoms and looking at a sample of the discharge under the microscope.

How can I prevent yeast infections?

Certain factors may increase your chance of developing a yeast infection. These factors don’t actually cause the problem, but they may create a situation that allows the yeast to grow rapidly.

  • Clothing: Tight jeans, nylon underwear, pantyhose, and wet bathing suits can hold in heat and moisture (two conditions in which yeast organisms thrive). Looser pants or skirts, 100% cotton underwear, and stockings may help avoid this problem.
  • Diet: Cutting down on sweets, milk products, and artificial sweeteners may reduce the risk of yeast infections.
  • Antibiotics: Antibiotics work by eliminating disease-causing organisms. While they are helpful in curing other problems, antibiotics may lead to an overgrowth of Candida in the vagina.
  • Pregnancy: Hormonal changes in the body during pregnancy encourage the growth of yeast. This is a very common time for an infection to occur. Until the baby is born, it may be hard to completely eliminate yeast infections. If you believe you are pregnant, tell your doctor.
  • Menstruation: Sometimes monthly changes in hormone levels may lead to yeast infections.
  • Diabetes: In addition to heat and moisture, yeast thrives on sugar. Because diabetics often have sugar in their urine, their vaginas are rich in this substance. Careful control of diabetes may help prevent yeast infection.

Controlling these factors can help eliminate yeast infections and may prevent them from coming back.

Some other helpful tips:

  1. For best results, be sure to use the medication as prescribed by your doctor, even if you feel better quickly.
  2. Avoid sexual intercourse, if your doctor advises you to do so. The suppository formulation may damage the diaphragm or latex condom. Therefore, use of the diaphragm or latex condom during therapy with the suppository is not recommended. Consult your physician.
  3. If your partner has any penile itching, redness, or discomfort, he should consult his physician and mention that you are being treated for a yeast infection.
  4. You can use the medication even if you are having your menstrual period. However, you should not use tampons because they may absorb the medication. Instead, use external pads or napkins until you have finished your medication. You may also wish to wear a sanitary napkin if the vaginal medication leaks.
  5. Dry the genital area thoroughly after showering, bathing, or swimming. Change out of a wet bathing suit or damp exercise clothes as soon as possible. A dry environment is less likely to encourage the growth of yeast.
  6. Wipe from front to rear (away from the vagina) after a bowel movement.
  7. Don’t douche unless your doctor specifically tells you to do so. Douching may disturb the vaginal balance.
  8. Don’t scratch if you can help it. Scratching can cause more irritation and spread the infection.
  9. Discuss with your physician any medication you are already taking. Certain types of medication can make your vagina more susceptible to infection.
  10. Eat nutritious meals to promote your general health.

Manufactured by Padagis®
Minneapolis, MN 55427

www.padagis.com

2204901
Rev 05-24

3B500 RC PH1

Package/Label Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 45802-717-08

Rx Only

Terconazole Vaginal Suppositories, 80 mg

3 SUPPOSITORIES with vaginal applicator

carton
carton

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
a1f2acc3-46a1-8c88-4468-5826c2e9fea6Product name120140508

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
45802-717-00EA - Each45802-7172d1becfb-6670-41a8-846b-9532b30b877212019-12-10
45802-717-08EA - Each45802-7173ee857ff-9984-40ea-873a-73ee5f1db07012012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
TERCONAZOLEACTIVE INGREDIENT0KJ2VE664U3
TERCONAZOLEACTIVE MOIETY0KJ2VE664U3
BUTYLATED HYDROXYANISOLEINACTIVE INGREDIENTREK4960K2U3
MEDIUM-CHAIN TRIGLYCERIDESINACTIVE INGREDIENTC9H2L21V7U3

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 3 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
45802-71745802-717-00, 45802-717-08

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 3 matching rows.

Source Document#

Source XML

Older Hydrated Versions#

Version, Effective date, Source table
VersionEffective dateSourceHydrated
142024-09-30full-release2026-05-31 21:31:24

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 1 · 57 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7UGEL / TOPICAL12 mgExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7UPOWDER, FOR SUSPENSION / ORAL3390 mg/5mlExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7UINJECTION, EMULSION / INTRAVENOUS1.1 %w/vExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7UOINTMENT / TOPICAL20 %w/wExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7USOLUTION / ORAL5566 mgExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7UPOWDER, FOR SUSPENSION / ORAL3390 mg/5mlExact identifier — unii candidate
54 equally ranked IID candidates
BUTYLATED HYDROXYANISOLEBUTYLATED HYDROXYANISOLEREK4960K2USUPPOSITORY / VAGINAL1 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7UINJECTION, SUSPENSION, EXTENDED RELEASE / SUBCUTANEOUS990.3 mgExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7ULOTION / TOPICAL7 %w/wExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7UFILM, EXTENDED RELEASE / TRANSDERMALNAExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7UAEROSOL, FOAM / TOPICAL10.87 %w/wExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7UPOWDER / SUBLINGUAL2 mgExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7UGEL / TOPICAL12 mgExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7USPRAY, METERED / SUBLINGUAL110 mgExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7UTABLET, EXTENDED RELEASE / ORAL0.37 mgExact identifier — unii candidate
54 equally ranked IID candidates
BUTYLATED HYDROXYANISOLEBUTYLATED HYDROXYANISOLEREK4960K2USUPPOSITORY / VAGINAL1 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
BUTYLATED HYDROXYANISOLEBUTYLATED HYDROXYANISOLEREK4960K2USUPPOSITORY / VAGINAL1 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7UCAPSULE / ORAL4771 mgExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7UTABLET, EXTENDED RELEASE / ORAL0.37 mgExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7UINJECTION, EMULSION / INTRAVENOUS1.1 %w/vExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7UTABLET / ORAL2 mgExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7UCAPSULE / ORAL4771 mgExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7UINJECTION, EMULSION / INTRAVENOUS1.1 %w/vExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7USUSPENSION / ORAL10170 mgExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7UCREAM / TOPICAL3300 mgExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7UTABLET, EXTENDED RELEASE / ORAL0.37 mgExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7UINJECTION, SUSPENSION, EXTENDED RELEASE / SUBCUTANEOUS990.3 mgExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7UAEROSOL, FOAM / TOPICAL10.87 %w/wExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7USUSPENSION / ORAL10170 mgExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7USOLUTION / ORAL5566 mgExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7UPOWDER / SUBLINGUAL2 mgExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7USPRAY, METERED / SUBLINGUAL110 mgExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7UPOWDER, FOR SUSPENSION / ORAL3390 mg/5mlExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7USOLUTION / ORAL5566 mgExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7USPRAY / TOPICAL540 mgExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7UFILM, EXTENDED RELEASE / TRANSDERMALNAExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7UCREAM / TOPICAL3300 mgExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7UCREAM / TOPICAL3300 mgExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7UTABLET / ORAL2 mgExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7UFILM, EXTENDED RELEASE / TRANSDERMALNAExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7USPRAY / TOPICAL540 mgExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7USUSPENSION / ORAL10170 mgExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7UTABLET / ORAL2 mgExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7UINJECTION, SUSPENSION, EXTENDED RELEASE / SUBCUTANEOUS990.3 mgExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7UPOWDER / SUBLINGUAL2 mgExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7UAEROSOL, FOAM / TOPICAL10.87 %w/wExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7UCAPSULE / ORAL4771 mgExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7UTABLET, ORALLY DISINTEGRATING / ORAL1 mgExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7UTABLET, ORALLY DISINTEGRATING / ORAL1 mgExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7UGEL / TOPICAL12 mgExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7UOINTMENT / TOPICAL20 %w/wExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7USPRAY, METERED / SUBLINGUAL110 mgExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7ULOTION / TOPICAL7 %w/wExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7USPRAY / TOPICAL540 mgExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7UTABLET, ORALLY DISINTEGRATING / ORAL1 mgExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7ULOTION / TOPICAL7 %w/wExact identifier — unii candidate
54 equally ranked IID candidates
MEDIUM-CHAIN TRIGLYCERIDESMEDIUM-CHAIN TRIGLYCERIDESC9H2L21V7UOINTMENT / TOPICAL20 %w/wExact identifier — unii candidate
54 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A077149-001TERCONAZOLETERCONAZOLE80MGSUPPOSITORY / VAGINALABRS2006-03-17

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A077149-001AB

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A077149-001TERCONAZOLE80MGSUPPOSITORY / VAGINALABRS2006-03-1784e616aacf4f…
2026-08-18 06:07:402026-07A077149-001TERCONAZOLE80MGSUPPOSITORY / VAGINALABRS2006-03-17caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A077149-001TERCONAZOLE80MGSUPPOSITORY / VAGINALABRS2006-03-17011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A077149-001TERCONAZOLE80MGSUPPOSITORY / VAGINALABRS2006-03-1731067a03dcf5…
2025-08-23 18:47 UTC2025-08A077149-001TERCONAZOLE80MGSUPPOSITORY / VAGINALABRS2006-03-176a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A077149-001TERCONAZOLE80MGSUPPOSITORY / VAGINALABRS2006-03-17fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A077149-001TERCONAZOLE80MGSUPPOSITORY / VAGINALABRS2006-03-17b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A077149-001TERCONAZOLE80MGSUPPOSITORY / VAGINALABRS2006-03-1703ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A077149-001TERCONAZOLE80MGSUPPOSITORY / VAGINALABRS2006-03-172680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A077149-001TERCONAZOLE80MGSUPPOSITORY / VAGINALABRS2006-03-175bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A077149-001TERCONAZOLE80MGSUPPOSITORY / VAGINALABRS2006-03-17d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A077149-001TERCONAZOLE80MGSUPPOSITORY / VAGINALABRS2006-03-17d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A077149-001TERCONAZOLE80MGSUPPOSITORY / VAGINALABRS2006-03-1779d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A077149-001TERCONAZOLE80MGSUPPOSITORY / VAGINALABRS2006-03-17301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A077149-001TERCONAZOLE80MGSUPPOSITORY / VAGINALABRS2006-03-171e350fbaab3a…
2024-05-31 18:47 UTC2024-05A077149-001TERCONAZOLE80MGSUPPOSITORY / VAGINALABRS2006-03-178072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A077149-001TERCONAZOLE80MGSUPPOSITORY / VAGINALABRS2006-03-175c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A077149-001TERCONAZOLE80MGSUPPOSITORY / VAGINALABRS2006-03-175d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A077149-001TERCONAZOLE80MGSUPPOSITORY / VAGINALABRS2006-03-174b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A077149-001TERCONAZOLE80MGSUPPOSITORY / VAGINALABRS2006-03-1774a2ff9319b5…
2022-03-09 01:35 UTC2022-03A077149-001TERCONAZOLE80MGSUPPOSITORY / VAGINALABRS2006-03-17bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A077149-001TERCONAZOLE80MGSUPPOSITORY / VAGINALABRS2006-03-17782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A077149-001TERCONAZOLE80MGSUPPOSITORY / VAGINALABRS2006-03-1787673890dc5c…
2021-03-12 10:30 UTC2021-03A077149-001TERCONAZOLE80MGSUPPOSITORY / VAGINALABRS2006-03-175aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A077149-001TERCONAZOLE80MGSUPPOSITORY / VAGINALABRS2006-03-178869cabd3fbd…
2020-11-12 02:37 UTC2020-11A077149-001TERCONAZOLE80MGSUPPOSITORY / VAGINALABRS2006-03-17c0c555d07b60…
2019-12-14 00:12 UTC2019-12A077149-001TERCONAZOLE80MGSUPPOSITORY / VAGINALABRS2006-03-173f01610625f2…
2019-09-15 20:21 UTC2019-09A077149-001TERCONAZOLE80MGSUPPOSITORY / VAGINALABRS2006-03-17b00525d2431f…
2019-07-19 19:46 UTC2019-07A077149-001TERCONAZOLE80MGSUPPOSITORY / VAGINALABRS2006-03-17ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A077149-001TERCONAZOLE80MGSUPPOSITORY / VAGINALABRS2006-03-176a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A077149-001TERCONAZOLE80MGSUPPOSITORY / VAGINALABRS2006-03-171c564ffb4f44…
2023-12-20 04:57 UTC2023-12A077149-001TERCONAZOLE80MGSUPPOSITORY / VAGINALABRS2006-03-17ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A077149-001TERCONAZOLE80MGSUPPOSITORY / VAGINALABRS2006-03-17a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A077149-001TERCONAZOLE80MGSUPPOSITORY / VAGINALABRS2006-03-179b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A077149-001TERCONAZOLE80MGSUPPOSITORY / VAGINALABRS2006-03-17a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A077149-001TERCONAZOLE80MGSUPPOSITORY / VAGINALABRS2006-03-173f0d92c62455…
2023-05-13 08:27 UTC2023-05A077149-001TERCONAZOLE80MGSUPPOSITORY / VAGINALABRS2006-03-17053a50430f4f…
2023-01-26 05:58 UTC2023-01A077149-001TERCONAZOLE80MGSUPPOSITORY / VAGINALABRS2006-03-173bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A077149-001TERCONAZOLE80MGSUPPOSITORY / VAGINALABRS2006-03-173a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A077149-001TERCONAZOLE80MGSUPPOSITORY / VAGINALABRS2006-03-17f41ea6bd6efb…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A077149-001AB184e616aacf4f…
2026-08-18 06:07:402026-07A077149-001AB1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A077149-001AB1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A077149-001AB131067a03dcf5…
2025-08-23 18:47 UTC2025-08A077149-001AB16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A077149-001AB1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A077149-001AB1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A077149-001AB103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A077149-001AB12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A077149-001AB15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A077149-001AB1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A077149-001AB1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A077149-001AB179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A077149-001AB1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A077149-001AB11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A077149-001AB18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A077149-001AB15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A077149-001AB15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A077149-001AB14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A077149-001AB174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A077149-001AB1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A077149-001AB1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A077149-001AB187673890dc5c…
2021-03-12 10:30 UTC2021-03A077149-001AB15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A077149-001AB18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A077149-001AB1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A077149-001AB13f01610625f2…
2019-09-15 20:21 UTC2019-09A077149-001AB1b00525d2431f…
2019-07-19 19:46 UTC2019-07A077149-001AB1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A077149-001AB16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A077149-001AB11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A077149-001AB1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A077149-001AB1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A077149-001AB19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A077149-001AB1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A077149-001AB13f0d92c62455…
2023-05-13 08:27 UTC2023-05A077149-001AB1053a50430f4f…
2023-01-26 05:58 UTC2023-01A077149-001AB13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A077149-001AB13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A077149-001AB1f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
TerconazoleTERCONAZOLEPadagis Israel Pharmaceuticals Ltd207e9cf2-e8ec-43d7-9c11-46283c9cdb372026-08-11Warnings, Adverse reactionsExact identifier
ndc (package): 45802-717-00
ndc (package): 45802-717-08
ndc (product): 45802-717
ndc11 (package): 45802071708
ndc11 (package): 45802071700
spl id: 006c6bda-594f-46ce-ba64-d075022ed4b4
spl set id: 207e9cf2-e8ec-43d7-9c11-46283c9cdb37

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.